# The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)

> **NCT05971732** · PHASE4 · UNKNOWN · sponsor: **China-Japan Friendship Hospital** · enrollment: 146 (estimated)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction
- Iron Deficiency
- Acute Heart Failure

## Interventions

- **DRUG:** Ferric derisomaltose
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05971732
- **Lead sponsor:** China-Japan Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-01
- **Primary completion:** 2024-08-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2023-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05971732

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05971732, "The Effects of Ferric Derisomaltose in Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life(COREVIVE-HFrEF)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05971732. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*